Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients
Share
Why It Matters
Fennec's medicine helped kids keep their hearing much better than before. When a medicine works better in tests, that is good news for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.